Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neuroscience ; 124(2): 327-39, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-14980383

RESUMO

Previously, we demonstrated that outward currents activated by calcium-induced calcium release (CICR) opposed depolarization-induced action potential (AP) generation in dissociated mudpuppy parasympathetic neurons [J Neurophysiol 88 (2002) 1119]. In the present study, we tested whether AP generation by depolarizing current ramps could be altered by dissipating the mitochondrial membrane potential and thus interrupting mitochondrial Ca2+ buffering. Exposure to the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP; 2 microM) alone or in combination with the mitochondrial ATP synthase inhibitor oligomycin (8 microg/ml), increased the latency to AP generation. Exposure to the electron transport chain inhibitor rotenone (10 microM) alone or in combination with oligomycin (8 microg/ml) similarly increased the latency to AP generation. CCCP and oligomycin or rotenone and oligomycin treatment caused rhodamine 123 loss from mitochondria within a few minutes, confirming that the mitochondrial membrane potential was dissipated during drug exposure. Oligomycin alone had no effect on the latency to AP generation and did not cause loss of rhodamine 123 from mitochondria. The increase in latency induced by CCCP and oligomycin was similar when recordings were made with either the perforated patch or standard whole cell patch recording configuration. Exposure to the endoplasmic reticulum Ca-ATPase inhibitor thapsigargin (1 microM), decreased the latency to AP generation. In cells pretreated with thapsigargin to eliminate CICR, CCCP and oligomycin had no effect on AP latency. Pretreatment with iberiotoxin (IBX; 100 nM), an inhibitor of large conductance, calcium- and voltage-activated potassium channels, reduced the extent of the CCCP- and oligomycin-induced increase in latency to AP generation. These results indicate that treatment with CCCP or rotenone to dissipate the mitochondrial membrane potential, a condition which should minimize sequestration of Ca2+ by mitochondria, facilitated the Ca(2+)-induced Ca2+ release activation of IBX-sensitive and IBX-insensitive conductances that regulate AP generation.


Assuntos
Potenciais de Ação/efeitos dos fármacos , Cálcio/metabolismo , Ácido Egtázico/análogos & derivados , Gânglios Parassimpáticos/citologia , Neurônios/efeitos dos fármacos , Oligomicinas/farmacologia , Potenciais de Ação/fisiologia , Compostos de Anilina/metabolismo , Animais , Carbonil Cianeto m-Clorofenil Hidrazona/farmacologia , Quelantes/farmacologia , Interações Medicamentosas , Ácido Egtázico/farmacologia , Inibidores Enzimáticos/farmacologia , Gânglios Parassimpáticos/efeitos dos fármacos , Iodobenzenos/farmacologia , Ionóforos/farmacologia , Potenciais da Membrana , Mitocôndrias/efeitos dos fármacos , Necturus , Neurônios/citologia , Técnicas de Cultura de Órgãos , Técnicas de Patch-Clamp/métodos , Tempo de Reação/efeitos dos fármacos , Rodamina 123/metabolismo , Rotenona/farmacologia , Desacopladores/farmacologia , Xantenos/metabolismo
2.
Science ; 293(5539): 2465-70, 2001 Sep 28.
Artigo em Inglês | MEDLINE | ID: mdl-11577238

RESUMO

Synapses in the central nervous system are usually defined by presynaptic exocytotic release sites and postsynaptic differentiations. We report here a demonstration of dendrodendritic inhibition that does not engage a conventional synapse. Using amperometric and patch-clamp recordings in rat brain slices of the substantia nigra, we found that blockade of the dopamine transporter abolished the dendritic release of dopamine and the resulting self-inhibition. These findings demonstrate that dendrodendritic autoinhibition entails the carrier-mediated release of dopamine rather than conventional exocytosis. This suggests that some widely used antidepressants that inhibit the dopamine transporter may benefit patients in the early stages of Parkinson's disease.


Assuntos
Proteínas de Transporte/metabolismo , Dendritos/metabolismo , Dopamina/metabolismo , Glicoproteínas de Membrana , Proteínas de Membrana Transportadoras , Proteínas do Tecido Nervoso , Substância Negra/metabolismo , Animais , Transporte Biológico/efeitos dos fármacos , Cálcio/metabolismo , Proteínas de Transporte/antagonistas & inibidores , Antagonistas dos Receptores de Dopamina D2 , Proteínas da Membrana Plasmática de Transporte de Dopamina , Estimulação Elétrica , Eletrofisiologia , Potenciais Evocados/efeitos dos fármacos , Potenciais Pós-Sinápticos Excitadores , Exocitose , Ácido Glutâmico/farmacologia , Humanos , Técnicas In Vitro , Potenciais da Membrana , Inibição Neural , Neurônios/metabolismo , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/metabolismo , Técnicas de Patch-Clamp , Piperazinas/farmacologia , Ratos , Receptores de Dopamina D2/metabolismo , Sódio/metabolismo , Substância Negra/citologia , Núcleo Subtalâmico/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...